Ocata Therapeutics Inc fka OCAT

[rocky301]

"ACT is working with the agency to fulfill the FDA's requirements to bring its RPE cell therapy into human clinical trials for the treatment of retinal degenerative diseases such as Retinitis Pigmentosa, Stargardt's disease, and dry age-related macular degeneration (AMD)."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=26460090&txt2find=retinitis|pigmentosa

"The retinal pigment epithelium is an important eye tissue, which plays a critical role in the pathogenesis of macular degeneration, retinitis pigmentosa and other retinal degenerative diseases. In the RCS rat, improvement in visual performance was 100 percent over untreated controls without any apparent adverse effects."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=35154852&txt2find=retinitis|pigmentosa

"We believe that we have a therapy that has multiple applications (retinal disease includes dry AMD, Retinitis Pigmentosa (RP) and Stargardt disease. The latter two may qualify as Orphan indications which could qualify for special treatment through the clinical process by the FDA. This was a large factor weighing in favor of selecting this therapeutic option."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=35960147&txt2find=retinitis|pigmentosa

One of ACTC's licensee's
OCEANSIDE, Calif., Jan 13, 2009 (BUSINESS WIRE) -- International Stem Cell Corporation (OTCBB: ISCO) has created layered human tissue from its unique parthenogenetic stem cells and transplanted this tissue into animals in pre-clinical trials to establish a potential new treatment for human retinal diseases, such as macular degeneration or retinitis pigmentosa.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=34779607&txt2find=retinitis|pigmentosa